



Correction

# Correction: Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPIA). *Microorganisms* 2022, 10, 127

Christian Theilacker <sup>1,\*</sup>, Mark A. Fletcher <sup>2</sup>, Luis Jodar <sup>1</sup> and Bradford D. Gessner <sup>1</sup>

<sup>1</sup> Pfizer Vaccines, 500 Arcola Rd., Collegetown, PA 19426, USA; luis.jodar@pfizer.com (L.J.); bradford.gessner@pfizer.com (B.D.G.)

<sup>2</sup> Pfizer Emerging Markets, 23-25 Avenue du Docteur Lannelongue, 75014 Paris, France; mark.a.fletcher@pfizer.com

\* Correspondence: christian.theilacker@pfizer.com; Tel.: +49-175-810-9049



**Citation:** Theilacker, C.; Fletcher, M.A.; Jodar, L.; Gessner, B.D. Correction: Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPIA). *Microorganisms* 2022, 10, 127. *Microorganisms* 2022, 10, 1018. <https://doi.org/10.3390/microorganisms10051018>

Received: 5 May 2022

Accepted: 10 May 2022

Published: 12 May 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

The authors wish to make the following corrections to this paper [1]:

After the publication of the manuscript, the authors recognized an error in the second paragraph of Section 3.1. The Trial Demonstrated PCV13 Efficacy for Prevention of First Episodes of VT CAP, Nonbacteremic/Noninvasive VT CAP and VT IPD. In the published version, it was stated that “For VT CAP, NB/NI VT CAP, and VT IPD, respectively, PCV13 demonstrated similar efficacy in the mITT population for first VT episodes (VE, 37.7%, 41.1% and 75.8%) and all VT episodes (VE 22.2%, 39.2% and 75.8%) [29].”

To the correct version, as follows:

“For VT CAP, NB/NI VT CAP, and VT IPD, respectively, PCV13 demonstrated similar efficacy in the mITT population for first VT episodes (VE, 37.7%, 41.1% and 75.8%) and all VT episodes (VE 37.5%, 39.2% and 75.8%) [14,29,30].”

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

## Reference

1. Theilacker, C.; Fletcher, M.A.; Jodar, L.; Gessner, B.D. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPIA). *Microorganisms* 2022, 10, 127. [[CrossRef](#)] [[PubMed](#)]